SCHEMBL25614598

SCHEMBL25614598

C[Si](C)(C)C#Cc1cncc(-n2cccn2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.40
ALDH1A1 P00352 3/20 0.40
NOTUM Q6P988 1/20 0.36
GRM5 P41594 3/20 0.34
MAPT P10636 2/20 0.33
MAPK1 P28482 1/20 0.33
MEN1 O00255 1/20 0.33
LMNA P02545 1/20 0.33
GAA P10253 1/20 0.33
G6PD P11413 1/20 0.33
KMT2A Q03164 1/20 0.33
NLRP3 Q96P20 1/20 0.33
TDO2 P48775 1/20 0.33
MET P08581 1/20 0.31
ICAM1 P05362 1/20 0.30
SELE P16581 1/20 0.30
VCAM1 P19320 1/20 0.30
CHRNA7 P36544 1/20 0.30
CHRNA10 Q9GZZ6 1/20 0.30
CHRNA9 Q9UGM1 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3429941 0.81 LMNA (0.40) KDM4EALDH1A1NOTUMGRM5MAPT
SCHEMBL30811674 0.78 KDM4E (0.44) KDM4EALDH1A1NOTUMGRM5MAPT
SCHEMBL25614588 0.78 KDM4E (0.44) KDM4EALDH1A1NOTUMGRM5MAPT
SCHEMBL25614466 0.78 GRM5 (0.31) GRM5
SCHEMBL30811694 0.78 GRM5 (0.31) GRM5
SCHEMBL25614363 0.78 CYP2A6 (0.41) KDM4EALDH1A1
SCHEMBL15884310 0.76 KDM4E (0.48) KDM4EALDH1A1NOTUMGRM5MAPT
SCHEMBL25614666 0.75 HTT (0.39) KDM4EALDH1A1GRM5MAPTGAA
SCHEMBL25615033 0.75 ADK (0.30)
SCHEMBL25614994 0.75 CA12 (0.39) GRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4582422-A1 METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF Global Health Drug Discovery Institute (CN) 2025-07-09 EP disclosed
US-20250214997-A1 METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF GLOBAL HEALTH DRUG DISCOVERY INSTITUTE (CN) 2025-07-03 US disclosed
US-20250002475-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS EPICS THERAPEUTICS (BE) 2025-01-02 US disclosed
US-12091400-B2 Piperidine derivatives as METTL3 inhibitors EPICS THERAPEUTICS (BE) 2024-09-17 US disclosed
US-20240270716-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS EPICS THERAPEUTICS (BE) 2024-08-15 US disclosed
WO-2024056099-A1 METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF 北京华益健康药物研究中心 2024-03-21 WO disclosed
CN-117720533-A MetTL3 inhibitor compound and pharmaceutical composition and application thereof 北京华益健康药物研究中心 2024-03-19 CN disclosed
WO-2023104209-A1 METTL3 INHIBITOR COMPOUND 上海昂阔医药有限公司 2023-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240270716-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS METTL3, METTL16, DIMT1 KDM4E 872/4885ALDH1A1 205/4885NOTUM 3641/4885
US-20250002475-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS METTL3, METTL16, DIMT1 KDM4E 872/4885ALDH1A1 205/4885NOTUM 3641/4885
US-12091400-B2 Piperidine derivatives as METTL3 inhibitors METTL3, METTL16, DIMT1 KDM4E 872/4885ALDH1A1 205/4885NOTUM 3641/4885
US-20250214997-A1 METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF METTL3, METTL14, METTL16 KDM4E 172/4885ALDH1A1 893/4885NOTUM 1554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.